July 6, 2026
BioNxt Solutions Inc.
ISIN: CA0909741062
BioNxt Advances GLP-1 Sublingual Semaglutide ODF Program with Next Stage of Delivery Development Underway
VANCOUVER, BC / ACCESS Newswire / July 6, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to...
Read more >>BioNxt Engages Business Development & Licensing Advisors for Commercialization of Patented Sublingual Cladribine ODF
VANCOUVER, BC / ACCESS Newswire / June 15, 2026 / BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that it has commenced work with a Business Development & Licensing (“BD&L”) specialist advisor to support the commercialization and...
Read more >BioNxt Advances Semaglutide ODF Program into Active Pharmaceutical Development
VANCOUVER, BC / ACCESS Newswire / May 19, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that its Semaglutide oral dissolvable film ("ODF") program has entered the active pharmaceutical development phase in collaboration with German...
Read more >BioNxt Applies Advanced Drug Delivery Strategy and Psychedelic Compound Library to Emerging Therapeutics Market Amid Accelerating Global Momentum
VANCOUVER, BC / ACCESS Newswire / April 28, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that it is evaluating opportunities to apply its proprietary drug delivery technologies to the emerging field of psychedelic therapeutics...
Read more >BioNxt Initiates GMP Manufacturing of Clinical-Grade Sublingual Cladribine Film Targeting Multiple Sclerosis (MS)
VANCOUVER, BC / ACCESS Newswire / April 14, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce the successful completion of Good Manufacturing Practice (GMP) manufacturing of its clinical-grade sublingual Cladribine oral thin film (ODF) at...
Read more >BioNxt Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 Countries
VANCOUVER, BC / ACCESS Newswire / April 7, 2026 / BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce the official registration of unitary effect for European Patent No. 4539857 covering the Company’s proprietary sublingual cladribine oral thin...
Read more >BioNxt Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 Countries
VANCOUVER, BC / ACCESS Newswire / April 7, 2026 / BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce the official registration of unitary effect for European Patent No. 4539857 covering the Company’s proprietary sublingual cladribine oral thin...
Read more >BioNxt Enters Commercialization Phase with Global Patent Protection and U.S. Fast Track Strategy for Sublingual Drug Delivery Platform
VANCOUVER, BC / ACCESS Newswire / March 24, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce a major advancement in its commercialization strategy, supported by a rapidly expanding global patent portfolio for its proprietary sublingual...
Read more >BioNxt Signs Strategic Agreement for Eurasian Commercialization Following Cladribine ODF Patent Grant in Eurasia and Europe
VANCOUVER, BC / ACCESS Newswire / March 17, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that it has signed a non-binding letter of intent (LOI) establishing an exclusive negotiation framework for the potential commercialization...
Read more >BioNxt Receives Milestone EPO Decision to Grant European Patent for Sublingual Cladribine Drug Delivery Technology for Multiple Sclerosis
VANCOUVER, BC / ACCESS Newswire / February 17, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that the European Patent Office (EPO) has issued a Decision to Grant European Patent No. 4539857 covering the Company's...
Read more >BioNxt Secures Innovative Chaperone Technology to Enhance Oral Thin-Film Drug Delivery
VANCOUVER, BC / ACCESS Newswire / February 5, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, today announced the signing of a non-binding letter of intent ("LOI") outlining a proposed transaction pursuant to which BioNxt would secure exclusive rights...
Read more >BioNxt Accelerates ODF for Multiple Sclerosis Toward Human Clinical Study with >40% Bioavailability Improvement and Myasthenia Gravis Expansion
VANCOUVER, BC / ACCESS Newswire / January 26, 2026 / BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce significant progress in the development of its proprietary lead cladribine oral thin film (ODF) program. Recent study results demonstrating...
Read more >